Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million (USD 27.7 million) in a Series B financing round. The round was led by Lapam Capital, with additional investments from Penglai Capital, Hermed Capital, Sunland Fund, and Sprinvest. The funds raised will be allocated towards clinical filings and trials, pipeline development, base construction, and team expansion.
Clinical and Pipeline Development Focus
Founded in 2018, BDgene is dedicated to the development of new drugs for refractory diseases across various therapeutic areas, including ophthalmology, nervous system, hematopoietic system, viral infection, and oncology. The company’s strategic investment will bolster its efforts in clinical development and enhance its drug pipeline, positioning BDgene as a leader in gene therapy and novel drug development.
BD111: A Milestone in Ophthalmic Treatment
BDgene’s flagship product, BD111, an ophthalmic injection for the treatment of herpes simplex virus type I stromal keratitis, has achieved significant regulatory milestones. In June of the previous year, BD111 received orphan drug designation (ODD) from the US FDA, followed by clinical approval in China in April of this year. These achievements underscore BDgene’s commitment to addressing unmet medical needs and improving patient outcomes in the field of ophthalmology.-Fineline Info & Tech
